文献

J-GLOBAL ID：201602275663097681   整理番号：16A1119109

T細胞リンパ腫の36人の患者におけるサリドマイドの臨床応用を分析した。【JST・京大機械翻訳】

Clinical analysis of thalidomide in 36 untreated patients with T- cell lymphoma

著者 (18件)： Huang Huiying (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Song Yuqin (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Zheng Wen (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Wang Xiaopei (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Xie Yan (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Lin Ningjing (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Tu Meifeng (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Zhang Chen (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Ping Lingyan (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Liu Weiping (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Ying Zhitao (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Deng Lijuan (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Ding Ning (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Wu Meng (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Sun Yingli (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Du Tingting (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Leng Xin (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute) ,  Zhu Jun (Laboratory of carcinogenesis and Translational Research. Ministry of Education of People’ s Republic of China, Lymphoma Department, Peking University Cancer Hospital and Institute)
資料名： Zhonghua Xueyexue Zazhi  (Zhonghua Xueyexue Zazhi)
巻： 37  号： 6  ページ： 529-531  発行年： 2016年 
JST資料番号： C2307A  ISSN： 0253-2727  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： 中国 (CHN)  言語： 中国語 (ZH)

抄録/ポイント： サリドマイドは抗血管新生及び免疫調節作用を有し、同時に一定の抗腫瘍作用を有する。20世紀90年代以来、サリドマイドはアメリカFDAが正式に多発性骨髄腫の治療に応用された。現在、多発性骨髄腫の一次治療に広く応用されている。近年,サリドマイドは難治性リンパ腫の治療に用いられている。本研究の目的は,非ホジキンリンパ腫(NHL)の治療におけるサリドマイド併用化学療法の有効性と安全性を調査することである。Data from the ScienceChina, LCAS.【JST・京大機械翻訳】

シソーラス用語： 安全性 ,  抗腫瘍作用 ,  *リンパ腫 ,  アメリカ合衆国 ,  *T細胞リンパ腫 ,  非Hodgkinリンパ腫 ,  血管新生 ,  多発性骨髄腫 ,  *患者 ,  芳香族カルボン酸 ,  免疫療法薬 ,  酸イミド ,  芳香族縮合化合物 ,  ジカルボン酸
準シソーラス用語： 多剤併用療法 ,  免疫調節作用 ,  *臨床応用 , 【Automatic Indexing@JST】

分類 (2件)： 血液の腫よう  (GK04000M) ,  腫ようの薬物療法  (GE03032C)

物質索引 (1件)： サリドマイド

タイトルに関連する用語 (6件)： T細胞リンパ腫 ,  患者 ,  サリドマイド ,  臨床 ,  応用 ,  分析